HYPOTENSION AND SYNCOPE IN CERTAIN SETTINGS
See full prescribing information for complete boxed warning.
- TRADE NAME: Addyi (Sprout)
- INDICATIONS: Hypoactive sexual desire disorder in premenopausal women
- CLASS: Serotonin type 1A receptor agonist, Serotonin type 2A receptor antagonist
- HALF-LIFE: 11 hours
- FDA APPROVAL DATE: 08/18/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Amprenavir, Atazanavir, Boceprevir, Carbamazepine, Ciprofloxacin, Clarithromycin, Conivaptan, Digoxin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil - PREGNANCY: No data available
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of flibanserin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
